MolecuLight, a Toronto, Canada-based provider of point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, raised an undisclosed amount in funding.
The round was led by BDC Capital and iGan Ventures.
The company intends to use the funds to support its continued global expansion to meet customer demand for its MolecuLight i:X® and DX™ devices.
Led by CEO Anil Amlani, MolecuLight is a medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercial devices include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement.
The MolecuLight devices are sold in North America through its direct sales and clinical applications team and internationally through MolecuLight’s 15 specialized distributors in 18 countries.
The company is also based in Pittsburgh, PA.
FinSMEs
15/08/2022